Krebs Biochemicals and Industries Limited (NSE: KREBSBIO) submitted its financial results for the quarter and year ended March 31, 2026, to the National Stock Exchange on May 21, 2026, following a Board meeting held on the same day. The filing marks the company's full-year FY26 earnings disclosure, though no dividend declaration accompanied the announcement.

Dividend History: A 21-Year Gap

The company's dividend record reflects a prolonged absence of shareholder payouts. The last and only dividend on record was declared on June 9, 2005, when the Board recommended a payout of ₹3.00 per share for FY2004-05, representing 30% of face value. Since that single declaration over two decades ago, Krebs Biochemicals has made no further dividend announcements. At the current market price of ₹55.30, that historical dividend would translate to a yield of approximately 5.42% on today's price, though this figure carries no present relevance given the absence of any recent payout.

Valuation and Sector Context

The stock currently trades at ₹55.30, up ₹0.14 (0.25%) on the day of the results announcement. Notably, the price-to-earnings ratio is currently not available, as the company's earnings data does not support a calculable PE multiple at this stage. Sector PE data is similarly unavailable for comparison. Investors are therefore unable to benchmark the stock's valuation against pharmaceutical or biochemical sector peers through conventional earnings multiples at this time.

52-Week Price Range and Market Position

The stock's 52-week trading range underscores significant price volatility. The 52-week high of ₹113.50 was recorded on June 9, 2025, while the 52-week low of ₹38.33 was touched as recently as March 30, 2026, just weeks before the results announcement. The current price of ₹55.30 sits approximately 51.3% below the annual peak and approximately 44.3% above the annual trough, indicating the stock is trading in the lower half of its annual range.

Market Capitalisation and Trading Activity

Krebs Biochemicals carries a market capitalisation of ₹119.23 Cr, placing it firmly in the small-cap segment. Trading volumes on the results day were thin, with only 1,231 shares changing hands. However, a strikingly high delivery percentage of 94.07% indicates that nearly all trades on the day resulted in actual delivery rather than intraday squaring off. This elevated delivery ratio in a low-volume session can suggest conviction among the limited number of participants transacting in the stock, though the absolute volume remains too low to draw broad conclusions about institutional interest.

Company Background

Krebs Biochemicals and Industries Limited is engaged in the manufacture of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company is headquartered in Andhra Pradesh and has been listed on NSE under the ISIN INE268B01013. With a daily volatility of 3.44%, the stock exhibits above-average price swings relative to its size, a factor investors in this segment must account for.

What This Means for Investors